WALTHAM, Mass.--(BUSINESS WIRE)--Jun 6, 2018--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters a 30-day option to purchase up to 645,000 additional shares of its common stock. The offering is expected to close on June 11, 2018, subject to customary closing conditions.

J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Canaccord Genuity LLC and JMP Securities LLC are acting as lead managers, and Nomura Securities International, Inc. and Raymond James & Associates, Inc. are acting as co-managers for the offering.

A registration statement relating to the offering has been filed with and declared effective by the Securities and Exchange Commission, or SEC, on June 6, 2018. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at prospectus-eq_fi@jpmchase.com or by telephone at (866) 803-9204, or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the anticipated closing date of the offering, the potential for our drug candidates to treat cancers and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the offering such as market conditions, the possibility that the closing conditions of the offering will not be met and/or that the parties will be unable to consummate the transaction on the anticipated terms or at all, that the cost of the transaction to the Company will be more than planned, the development of our drug candidates, our ability to successfully demonstrate the efficacy and safety of our drug candidates and other risks identified in our SEC filings, including our Registration Statement on Form S-1 filed with the SEC on June 4, 2018, as amended, our Annual Report on Form 10-K for the year ended December 31, 2017, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606006484/en/

CONTACT: Media:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com

or

Investor Relations:

Argot Partners

Laura Perry or Sam Martin, 212-600-1902

Laura@argotpartners.comorSam@argotpartners.com

or

Company:

Deciphera Pharmaceuticals, Inc.

Christopher J. Morl, 781-209-6418

Chief Business Officer

cmorl@deciphera.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES FINANCE GENERAL HEALTH

SOURCE: Deciphera Pharmaceuticals, Inc.

Copyright Business Wire 2018.

PUB: 06/06/2018 10:31 PM/DISC: 06/06/2018 10:31 PM

http://www.businesswire.com/news/home/20180606006484/en